The Series C round was co-led by Parkwalk Advisors and the Boehringer Ingelheim Venture Fund to support international expansion and clinical studies.
"We would like to thank all the investors that participated, including Parkwalk and Boehringer Ingelheim Venture Fund for their continued support, and welcome Hostplus, all of whom recognise the transformative impact that our technology can have on treatment for stroke and lung fibrosis patients. We will continue to harness our position and experience as a European market leader to achieve broad success in the US, helping improve patient care and access to life-changing therapies."
The funding round was led by Parkwalk Advisors with participation from the Finance Durham Fund and NPIF II Maven Equity Finance.
"We are delighted to close out this first phase of our investment round with the support of Parkwalk and Maven. Maven are joining us at what is a very exciting time in our journey as we head towards a new chapter. Having worked with Parkwalk for 6 years, it’s fantastic to carry on our strong relationship as we deliver on our ambitious plans. The growth we have seen in recent years is a testament to our market leading innovation and we can’t wait to use this investment to take the business to the next level."
The capital injection will accelerate the silicon roadmap for minimally invasive neural implant applications.
"Our semiconductor-based approach is fundamentally reshaping what neural implants can achieve. By offering a customisable, compact solution that integrates seamlessly into medical devices, we’re empowering a new era of neural interfaces that are not only more powerful but also less invasive. This marks a transformative shift in neurological care."
The oversubscribed round was anchored by IP Group, Parkwalk Advisors, and AlbionVC.
"There is a massive market opportunity for start-ups that figure out how to harness the potential of AI to transform how software gets built, tested, and deployed. Our investment in the company reflects our belief in its potential to be an important player in the next generation of AI-powered software development tools."
Parkwalk Advisors led the round with a £1.5m investment alongside a £700k grant from Innovate UK.
"AI as a technology block has huge potential in the sleep tech industry and equally the specific ScentTech sector within that, in which OW is a leader. ML and AI are opening up capabilities of predictions and data integration merging patterns from individual real-time biofeedback with many other core variables around sleep, user profile and environment. OW’s AI engine has been in development for over 5 years. Able to model multiple scent designs through the sleep cycle but taking into account all the huge factors noted above using predictive modelling and database analysis to deliver highly optimised and individual point solutions."
